Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH), Eli Lilly & Co (LLY) and Elevance Health (ELV)
Truist Financial Sticks to Its Buy Rating for Elevance Health (ELV)
Leerink Partners Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $463
Elevance Health: Buy Rating Affirmed Amid Favorable Outlook and Strategic Adjustments
Baird Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $529
TD Cowen Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $484
Morgan Stanley Adjusts Elevance Health Price Target to $428 From $405, Maintains Equal Weight Rating
Elevance Health Analyst Ratings
Baird Downgrades Elevance Health to Neutral From Outperform, Adjusts Price Target to $529 From $625
Truist Financial Maintains Elevance Health(ELV.US) With Buy Rating, Raises Target Price to $510
Truist Securities Maintains Buy on Elevance Health, Raises Price Target to $510
Barclays Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $512
Barclays Sticks to Its Buy Rating for Elevance Health (ELV)
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Announces Target Price $505
Elevance Health Analyst Ratings
Mizuho Maintains Outperform on Elevance Health, Raises Price Target to $505
Guggenheim Initiates Elevance Health at Buy With $518 Price Target
Truist Financial Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $480
Cantor Fitzgerald Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $485
Truist Financial Sticks to Their Buy Rating for Elevance Health (ELV)